← Leaderboards
Seth J Field
Beth Israel Deaconess Medical Center
$7,731,774
Attributed
$9,360,242
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,360,242 · 7
By mechanism
R01$6,274,650 · 4
DP2$2,317,500 · 1
K08$615,832 · 1
R03$152,260 · 1
Top collaborators
- Michael Jackson5 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Lewis C Cantley$35,988,650
- Fredric E. Wondisford$29,129,494
- Sergei Y Sokol$26,713,454
- John V Frangioni$42,386,239
- Henry N Higgs$16,490,245
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSignal TransductionPathway InteractionsInsightTraffickingCell MembraneGolgi ApparatusVesicleCellsPhosphatidylinositolsOncogenesF-ActinRegulationCancer CellAffectNew Therapeutic TargetCell Culture TechniquesComplexGolph3 GeneOncogenicProteinsMorphologyImpairmentHigh Throughput Screening
Grant awards (23)
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$519,807
R01 · FY2024 · CA · contact PI
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$608,794
R01 · FY2023 · CA · contact PI
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$655,747
R01 · FY2022 · CA · contact PI
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$733,096
R01 · FY2021 · CA · contact PI
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$739,493
R01 · FY2020 · CA · contact PI
GOLPH3 Pathway Regulation of Golgi Structure and Function$325,500
R01 · FY2019 · GM · contact PI
High Throughput Screen to Identify Inhibitors of the Golgi GOLPH3 Pathway$391,163
R01 · FY2018 · CA · contact PI
GOLPH3 Pathway Regulation of Golgi Structure and Function$325,500
R01 · FY2018 · GM · contact PI
High Throughput Screen to Identify Inhibitors of the Golgi GOLPH3 Pathway$400,312
R01 · FY2017 · CA · contact PI
GOLPH3 Pathway Regulation of Golgi Structure and Function$325,500
R01 · FY2017 · GM · contact PI
High Throughput Screen to Identify Inhibitors of the Golgi GOLPH3 Pathway$423,213
R01 · FY2016 · CA · contact PI
GOLPH3 Pathway Regulation of Golgi Structure and Function$325,500
R01 · FY2016 · GM · contact PI
Targeting a Novel Phosphoinositide Signaling Pathway for Cancer Therapy$252,173
R01 · FY2010 · CA · contact PI
Targeting a Novel Phosphoinositide Signaling Pathway for Cancer Therapy$248,852
R01 · FY2009 · CA · contact PI
Phosphoinositides Provide Unique Insights into Cell Biology and Pathophysiology$2,317,500
DP2 · FY2008 · OD · contact PI
PI-3-kinase mediated signaling by insulin and IGF-1$121,770
K08 · FY2007 · DK · contact PI
PI-3-Kinase Signaling over Physiologic Time-Scales/Response to Insulin or IGF-1$75,010
R03 · FY2007 · DK · contact PI
PI-3-kinase mediated signaling by insulin and IGF-1$121,770
K08 · FY2006 · DK · contact PI
PI-3-Kinase Signaling over Physiologic Time-Scales/Response to Insulin or IGF-1$77,250
R03 · FY2006 · DK · contact PI
PI-3-kinase mediated signaling by insulin and IGF-1$122,850
K08 · FY2005 · DK
PI-3-kinase mediated signaling by insulin and IGF-1$80,554
K08 · FY2004 · DK
PI-3-kinase mediated signaling by insulin and IGF-1$44,295
K08 · FY2004 · DK
PI-3-kinase mediated signaling by insulin and IGF-1$124,593
K08 · FY2003 · DK